Biotech · Private company · West Chester, PA, US
Molecular Targeting Technologies, Inc.
Track this companyFree. Adds Molecular Targeting Technologies, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- 177Lu-DOTA-EB-TATEPhase 1 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
- Amino Acid SolutionPhase 1 · Neuroendocrine TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine TumorsPHASE1 · COMPLETED · started Jun 18, 2022ClinicalTrials.gov NCT05475210 · fetched Nov 12, 2026
NIH awards1
- Targeted radionuclide therapy for non-small cell lung cancer with Lu-177 EBRGDFiscal year 2026 · $637.5KNIH RePORTER 1R01CA299133-01 · fetched Nov 12, 2026